Unuric 40mg Tablet

Unuric 40mg Tablet contains Febuxostate as an active ingredient which is a xanthine oxidase inhibitor. This medicine is used to prescribes to treat and prevent gout. A high level of uric acid in the body may result in gout, that can cause pain by forming crystals around the kidneys and joints.

This medication helps in keeping low uric acid levels. It works by blocking the action of enzyme responsible for uric acid formation. It should be taken with food in dose and duration as advice by the doctor. Don't take more than the recommended dose.​

• Treatment of Gout

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Unuric 40mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Nausea
• Skin rash
• Abnormal liver function
• Joint pain
• Rash

Seek medical attention in case of any unusual or severe side effects immediately.

• Doctor determines the exact dose and duration with Unuric 40mg Tablet as per the overall health condition of the patient. This tablet should be taken with food or after food, but at the fix time every day to get effective results.
• Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.​​
  

• Unuric 40mg Tablet contains Allopurinol as an active ingredient which is a xanthine oxidase inhibitor.
• It works by blocking the action of enzyme responsible for uric acid formation and preventing future attacks rather than treating acute or active pain. This medication helps in keeping low uric acid levels.​​
  

• Schumacher Jr, H. R., Becker, M. A., Lloyd, E., MacDonald, P. A., & Lademacher, C. (2009). Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology, 48(2), 188-194. https://pubmed.ncbi.nlm.nih.gov/19141576/
• Hu, M., & Tomlinson, B. (2008). Febuxostat in the management of hyperuricemia and chronic gout: a review. Therapeutics and clinical risk management, 4(6), 1209-1220. https://pubmed.ncbi.nlm.nih.gov/19337428/
• Robinson, P. C., & Dalbeth, N. (2018). Febuxostat for the treatment of hyperuricaemia in gout. Expert opinion on pharmacotherapy, 19(11), 1289-1299. https://pubmed.ncbi.nlm.nih.gov/30024787/
• Frampton, J. E. (2015). Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs, 75(4), 427-438. https://pubmed.ncbi.nlm.nih.gov/25724536/
• Edwards, N. L. (2009). Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology, 48(suppl_2), ii15-ii19.